DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Objectives:
- To determine the safety, tolerability and maximum tolerated dose (MTD) of oral temozolomide
using a 7 days on and 7 days off regimen combined with intrathecal liposomal cytarabine
(DepoCyt) in patients with neoplastic meningitis from solid tumors and systemic lymphoma.